Many properties of an antibody can be predictably and affordably engineered but not epitope specificity. Abveris provides an advantage for our partners by delivering monoclonal antibodies targeting a more diverse spread of epitopes than traditional in-vivo systems can provide.
The antibodies Abveris delivers are murine and will need to be humanized before going into the clinic. As humanization technologies continue to become more reliable, the importance of targeting the exact epitope of interest is more and more critical.
In addition to diversity, Abveris provides a time advantage. In as little as 45 days we deliver a panel of specific mAbs for our partners to take into their next-level assays. With many companies competing for IP and market share with drugs against a limited number of targets, time is critical.
We listen to what you need and set up a project plan accordingly. We can screen using one or a combination of:
All antibodies discovered in our collaborations are owned by our partners. Fully royalty and milestone free!
Contact our team so that together we can develop a custom workflow. Our goal is to get you the antibodies you need every time. That usually means applying our expertise in a flexible way and working with our collaborators in the way that serves their needs best.